Clinical ink Announces Strategic Investment from Ardan Equity and GI Partners to Accelerate Next Phase of Growth

Global clinical trial technology leader Clinical ink recently announced that it had secured investments from Ardan Equity and GI Partners, with the two companies investing new equity in a co-control partnership. Ardan Equity made its investment in Clinical ink through its private fund "Ardan Equity Fund I" while GI partners has been an investor in Clinical ink since August 2020 via its fund "GI Partners Fund V." With this new investment, existing investors, including GI Partners, completed a full exit of their previous investments, with Ardan and GI now collaborating with co-control to continue global growth of the Clinical ink platform, as well as to "pursue opportunities across clinical research and care, and deliver innovative solutions that meet the rapidly evolving needs of the industry, while maintaining the highest standards of quality and compliance."

Clinical ink's Chief Executive Officer Jonathan Goldman, MD expressed his enthusiasm with the announcement in the company's press release, stating "The management team and I are excited to work closely with Ardan and GI Partners to drive the next chapter of Clinical ink's evolution. We were impressed with Ardan's expertise, capabilities, and commitment to our company's growth. Our team is delighted that our long-term investors at GI remain with us given their longstanding experience with the company and its growth plans. The new investment by Ardan and GI represents a very positive development for our customers, the patients they serve, and the Clinical ink team."

Founded in 2007 and based out of Winstom-Salem, North Carolina, Clinical ink has worked hard to establish itself as a global leader in the life sciences industry, specializing in a variety of clinical trial areas including Direct Data Capture, telehealth, neurocognitive testing, and much more. For more information on this story, view the company's press release below.

See related materials:

• Clinical ink press release
• Clinical ink website
• Clinical ink LinkedIn